Understanding the Market | JW THERAP-B rose over 10% as reports suggest its CAR-T drug is expected to enter the commercial insurance catalog

JW THERAP-B rose over 10%, as of the time of writing, it increased by 9.77%, priced at HKD 3.82, with a transaction volume of HKD 4.6331 million. According to a report by Yicai, on November 2, it was learned that JW THERAP's CAR-T cell drug, Rukiyolunase injection, is making smooth progress in negotiations to enter the commercial health insurance innovative drug catalog, with hopes of being included in the catalog, reducing the medication burden for patients and benefiting more patients. This is the first domestically approved Class 1 CAR-T in China, with a post-listing price of 1.29 million yuan per injection. On October 30, JW THERAP announced the signing of a strategic cooperation supplementary agreement with Regeneron Pharmaceuticals. This revision not only marks an important upgrade in the long-term cooperative relationship between the two parties but also opens a new phase of collaboration in TCR-T cell therapy and platform technology innovation. Through this supplementary agreement, JW THERAP will receive payments of up to USD 50 million, including milestone payments for MAGE-A4 product development, drug production process supervision milestone payments, option exercise fees, and milestone payments for lentiviral vector manufacturing processes